Boryung said it has appointed current Chief Operating Officer (COO) Park Yun-sik as Executive Vice President in charge of its core pharmaceutical business.

In his new role, Park will oversee the entire Pharma division, including sales, manufacturing, development, and operations of Boryung’s prescription drug portfolio. The company said it aims to accelerate its growth strategy by unifying its corporate direction under Park’s leadership and expertise.

Park brings extensive experience in corporate operations and finance. He previously served as an outside director at Boryung for five years and has held key positions at KPMG, Macquarie Securities and Asset Management, and Lutronic Corporation. Since joining Boryung as COO in early 2023, he has led various initiatives to enhance organizational efficiency and drive internal innovation.

“This appointment is aimed at strengthening the execution of our mid-to-long-term business strategies while laying the foundation for sustainable growth based on financial soundness,” Boryung CEO Kim Jung-gyun said. “We will continue to foster strategic business areas for future growth while enhancing the fundamentals and securing growth momentum in our core Pharma business.”